COMMUNIQUÉS West-GlobeNewswire

Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
11/03/2024
ClearPoint Prism Now Being Used with Recently FDA Cleared and Launched SmartFrame Array® 1.2 Software SOLANA BEACH, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a [...]
Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration
11/03/2024
Lu-177 shipments expected to begin early 2025, followed by Ac-225 WEST VALLEY CITY, Utah, March 11, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of medical radioisotopes, cut the ribbon [...]
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
11/03/2024
Recently completed financing provides sufficient funds for near-term Parkinson’s Disease priority Plans for Phase 2b trial of NE3107 as first-line monotherapy for Parkinson’s Disease being finalized with targeted launch [...]
DiagnaMed Accelerates Commercialization Initiatives of CERVAI™ Brain Health AI Solution
11/03/2024
TORONTO, March 11, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), an artificial intelligence digital healthcare company, is pleased to announce that it has [...]
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
11/03/2024
SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “ Company ”) announces that its wholly-owned subsidiary, IntelGenx Corp. (“ IntelGenx Corp. ”), has [...]
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
11/03/2024
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer [...]
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
11/03/2024
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data from a subset of the [...]
Applied UV’s Subsidiary Files Patent Application for New Industry Disruptive Integrated Disinfection System for Healthcare Facilities
11/03/2024
Aligns with Company’s strategic focus on bringing to market state-of-the-art advanced disinfection systems NEW YORK, NY, March 11, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Applied UV, Inc. (“Applied UV” or the “ [...]
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
11/03/2024
Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel [...]
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
11/03/2024
Commercial launch of INPEFA ® (sotagliflozin) continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of LX9211 [...]
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
11/03/2024
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced it has entered into a securities purchase agreement (the “purchase agreement”) for a [...]
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
11/03/2024
Submission is based on 2-year confirmatory results from the Phase 3 PROTECT Study in which FILSPARI demonstrated a significant reduction in proteinuria, preservation of kidney function and a generally well-tolerated [...]
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
11/03/2024
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: [...]
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
11/03/2024
Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today [...]
Microbix Unveils Test Controls for Head and Neck Cancer
11/03/2024
HPV-related Tissue-Sample Mimics for QC of histology and PCR analyses MISSISSAUGA, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix ® ), a life sciences innovator, [...]
Transactions in connection with share buy-back program
11/03/2024
Company Announcement COPENHAGEN, Denmark; March 11, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock [...]
Major shareholder announcement – BlackRock, Inc.
11/03/2024
ANNOUNCEMENT NO. 253 Major shareholder announcement Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec [...]
Recursion Announces Plans to Open New Office in London
11/03/2024
Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King’s [...]
SAFE - Bond financing agreement in a minimum amount of €850,000 to support the Group’s turnaround strategy
11/03/2024
Bond financing agreement in a minimum amount of €850,000 to support the Group’s turnaround strategy Eragny-sur-Oise – France – March 11, 2024, 8.00 a.m. Safe SA (the “Company” ) announces that it has arranged flexible [...]

Pages